Abstract
SGLT2 inhibitors represent a novel therapeutic approach for the tretment of type 2 diabetes mellitus. Beyond glucose control, these drugs also induce weight loss and blod pressure reduction. In a specific cardiovascular outcome trial (EMPA-REG-OUTCOME), the SGLT 2 inhibitor empagliflozin has for the first time demonstrated to reduce cardiovascular and overall mortality as well as hospitalization for heart failure in patients with type 2 diabetes and high cardiovascular risk. These results will drastically affect future recommendations for the treatment of type 2 diabetes mellitus.).
© Georg Thieme Verlag KG Stuttgart · New York.
MeSH terms
-
Administration, Oral
-
Benzhydryl Compounds / therapeutic use*
-
Blood Glucose / metabolism
-
Blood Pressure / drug effects
-
Cardiovascular Diseases / blood
-
Cardiovascular Diseases / drug therapy*
-
Cardiovascular Diseases / mortality
-
Clinical Trials as Topic
-
Diabetes Mellitus, Type 2 / blood
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Diabetes Mellitus, Type 2 / mortality
-
Glucosides / therapeutic use*
-
Heart Failure / drug therapy
-
Heart Failure / mortality
-
Humans
-
Hypoglycemic Agents / therapeutic use*
-
Sodium-Glucose Transporter 2
-
Sodium-Glucose Transporter 2 Inhibitors*
-
Survival Rate
-
Treatment Outcome
-
Weight Loss / drug effects
Substances
-
Benzhydryl Compounds
-
Blood Glucose
-
Glucosides
-
Hypoglycemic Agents
-
SLC5A2 protein, human
-
Sodium-Glucose Transporter 2
-
Sodium-Glucose Transporter 2 Inhibitors
-
empagliflozin